Li Qing

"Cell therapy as an industry continues to refine and evolve in China with vast potential to change the ways various diseases are treated. GE continues investing in technologies and services aimed at the thriving cell therapy industry with a firm commitment of making these promising therapies accessible through successful industrialization. We are pleased to partner with CBMG, a leader in CAR-T and stem cell development in China and to take advantage of their excellent CMC cell production capabilities. Collaboration with ambitious partners like CBMG who share our vision is necessary for advancing innovation and delivering comprehensive manufacturing solutions for cell and regenerative medicines."

Li Qing
General Manager,
GE Healthcare Life Sciences,
Greater China

GE Healthcare Life Sciences, China, and Cellular Biomedicine Group Inc. (CBMG) have established a strategic research collaboration to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. In connection with the collaboration, a joint laboratory within CBMG's new Shanghai Zhangjiang GMP-facility will be established and dedicated to the joint research and development of a functionally integrated and automated immunotherapy cell preparation system.

CBMG and GE Healthcare Life Sciences, China, plan to develop state-of-the-art automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG's GMP facilities in Shanghai, Wuxi, and Beijing. The co-development activity will aim to standardize the delivery of cell manufacturing to potentially improve throughput, alleviate cost burdens and to minimize variability in cell production, which may increase the availability of engineered cells upon commercialization.

This partnership combines CBMG's scientific expertise in the manufacturing of CAR-T and stem cell production in China and GE Healthcare's renowned expertise in the design and development of innovative manufacturing technologies for the biopharmaceutical industry.


10 Diagnostic Imaging Trends for 2018

Video

 

Digital version